Open an account

Strata Critical Medical

SRTA · NASDAQ

$4.69+$0.15 (+3.30%)TodayMarket closed ·
Prev close $4.54

About SRTA

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the U.S. healthcare industry. The company is headquartered in New York City, New York and currently employs 601 full-time employees. The company went IPO on 2019-09-17. The firm focuses on the contractual and macro-non-correlated marketplaces for organ logistics and other medical services. Its subsidiary, Trinity Medical Solutions (Trinity), is engaged in the air and ground transportation of human organs for transplant, leveraging its asset-light platform to deliver logistics solutions to its customers across the United States. Trinity provides Organ Placement Services (TOPS) and Logistics Solutions for Transplant Centers and organ procurement organizations (OPOS). The firm also offers a full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services.

Employees
601
Headquarters
New York City, New York
Listed
Sep 17, 2019
Sector
Health Care
Industry
Health Care Providers & Services
Website
stratacritical.com

SRTA key statistics

Market cap
414.91M
Price-earnings ratio
9.27
Dividend yield
—
Average volume
918.14K
Volume
579.63K
Open price
$4.56
High today
$4.70
Low today
$4.54
52 Week high
$6.50
52 Week low
$3.95

Strata Critical Medical (SRTA) at a glance

As of Oct 20, 2026, Strata Critical Medical (SRTA) shares are priced at $4.69, giving the company a market cap of 414.91M and a price-to-earnings ratio of 9.27.

Today the stock has traded between $4.54 and $4.70. The current price is 3.3% above the day's low and 0.2% below its high.

Volume so far is 579.63K shares, below the average of 918.14K shares a day.

Over the past year Strata Critical Medical has ranged from $3.95 to $6.50, and now sits 29% of the way up that range.

Strata Critical Medical met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of $0.0079.

The average analyst price target is $9.75, 108.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $9.75
Low
$8.08
Now
$4.69
High
$13.39

SRTA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 93.8% on average.

  1. Q3 FY24: reported -$0.03 per share against an estimate of -$0.0485
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.104
  3. Q1 FY25: reported -$0.04 per share against an estimate of -$0.1142
  4. Q2 FY25: reported -$0.05 per share against an estimate of -$0.0449
  5. Q3 FY25: reported -$0.05 per share against an estimate of -$0.0255
  6. Q4 FY25: reported -$0.12 per share against an estimate of -$0.0255
  7. Q1 FY26: reported $0.03 per share against an estimate of -$0.0383
  8. Q2 FY26: reported -$0.12 per share against an estimate of $0.0079

SRTA news

  • Avi Kapoor

    Crude Oil Jumps 3%; Citizens Financial Earnings Top Views

  • Strata Critical Medical Q1 2026 Earnings Call: Complete Transcript

  • Earnings Outlook For Strata Critical Medical

  • Avi Kapoor

    Why Oracle Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Strata Critical Medical to Present at the 2025 Jefferies Industrials Conference

Similar companies

Companies in the same industry as Strata Critical Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.